MX1013
|
|
- CAS号:
- 223568-55-6
- 英文名:
- EP-1013
- 英文别名:
- F 1013;EP-1013;EP1013,EP-1013;EP1013 (F1013);Z-VD-FMK (mixture of isomers);(3S)-5-Fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxopentanoic acid;Pentanoic acid, 5-fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxo-, (3S)-
- 中文名:
- MX1013
- 中文别名:
- 化合物 T11210;EP1013 (F1013);EP-1013;F1013;MX-1013;(3S)-5-氟-3-[[(2S)-3-甲基-1-氧代-2-[[(苯基甲氧基)羰基]氨基]丁基]氨基]-4-氧代戊酸
- CBNumber:
- CB42627805
- 分子式:
- C18H23FN2O6
- 分子量:
- 382.38
- MOL File:
- 223568-55-6.mol
|
|
|
MX1013化学性质
-
沸点:
-
639.8±55.0 °C(Predicted)
-
|
-
密度:
-
1.258±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO : ≥ 60 mg/mL (156.91 mM)
-
|
-
酸度系数(pKa):
-
3.92±0.19(Predicted)
-
|
-
形态:
-
Solid
-
|
-
颜色:
-
White to off-white
-
|
MX1013性质、用途与生产工艺
EP1013 是一种广谱的 caspase 选择性抑制剂,可用于 1 型糖尿病研究。
EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal
rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function.
MX1013
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/08/19 | HY-10397 | MX1013 EP1013 | 223568-55-6 | 1 mg | 1100元 |
2024/08/19 | HY-10397 | MX1013 EP1013 | 223568-55-6 | 10mM * 1mLin DMSO | 1851元 |
223568-55-6, MX1013 相关搜索:
- 抑制剂
- EP1013 (F1013)
- 化合物 T11210
- EP-1013;F1013;MX-1013
- (3S)-5-氟-3-[[(2S)-3-甲基-1-氧代-2-[[(苯基甲氧基)羰基]氨基]丁基]氨基]-4-氧代戊酸
- 223568-55-6
- EP1013,EP-1013
- EP1013 (F1013)
- Pentanoic acid, 5-fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxo-, (3S)-
- Z-VD-FMK (mixture of isomers)
- F 1013
- (3S)-5-Fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxopentanoic acid
- EP-1013